NEWTON, Mass.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it will present at Digestive Disease Week May 19-22, 2012, in San Diego, CA. Peter G Traber, MD, President, CEO and CMO of Galectin, will present “Galectin Inhibition: a Promising New Strategy to Treat NASH and Liver Fibrosis” at the Product Theater on May 21, 2012, at 2 pm PT. Dr. Traber will discuss the role of galectins in the pathogenesis of non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, and how the Company’s galectin inhibitor compounds have been efficacious in preclinical models of disease. The broad effect of galectin inhibitors in preclinical models on all parameters of NASH liver injury, including fat deposition, liver cell death, inflammation and fibrosis makes this class of compounds particularly attractive drug candidates. In addition, Galectin Therapeutics will host Booth #3424 in Exhibit Hall E.
